Market Overview

Illumina Granted Review in Patent Litigation Against Complete Genomics

Illumina (NASDAQ: ILMN) announced that Magistrate Judge Elizabeth
D. Laporte of the U.S. District Court for the Northern District of
California granted Illumina's request to file a motion seeking
reconsideration of the Court's October 16, 2012 ruling invalidating
certain claims of U.S. Patent No. 6,306,597, which is being asserted by
Illumina against Complete Genomics, Inc. Under Judge Laporte's order,
Illumina is permitted to file briefing asking the Court to reconsider
its earlier ruling invalidating claims 14 and 15 of the ‘597 patent.
Illumina will seek a January 8, 2013 hearing date on the motion for
reconsideration.

Jay Flatley, Illumina's President and CEO, stated, “We are very pleased
that the Court has agreed to review

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (ILMN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters